Bristol Myers Squibb Shares Sold by Franklin Street Advisors

Institutional investor reduces stake in pharmaceutical company

Apr. 9, 2026 at 8:24am

Got story updates? Submit your updates here. ›

An extreme close-up of gears, levers, and other heavy industrial machinery, representing the complex financial systems underlying the pharmaceutical industry.The intricate financial machinery behind pharmaceutical investments is exposed in this dramatic industrial close-up.Princeton Today

Franklin Street Advisors Inc. NC, a North Carolina-based investment firm, significantly reduced its holdings in Bristol Myers Squibb Company (NYSE: BMY) by 98.1% in the fourth quarter, according to a recent SEC filing. The firm now owns just 8,954 shares of the biopharmaceutical company's stock, down from over 458,000 shares previously.

Why it matters

This filing indicates a shift in institutional investor sentiment around Bristol Myers Squibb, one of the largest pharmaceutical companies in the world. The significant reduction in Franklin Street's position could signal broader concerns about the company's outlook or valuation among some investors.

The details

According to the 13F filing, Franklin Street Advisors sold 458,206 shares of Bristol Myers Squibb during the fourth quarter, leaving the firm with just 8,954 shares valued at $483,000 as of the end of 2025. The filing does not provide specific reasons for the portfolio changes.

  • The 13F filing covers the fourth quarter of 2025.
  • Franklin Street Advisors previously held over 458,000 shares of Bristol Myers Squibb.

The players

Franklin Street Advisors Inc. NC

A North Carolina-based investment management firm that significantly reduced its stake in Bristol Myers Squibb in Q4 2025.

Bristol Myers Squibb Company

A global biopharmaceutical company headquartered in Princeton, New Jersey, focused on developing and delivering medicines for serious diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We must remain vigilant in our portfolio management to ensure we are positioned for the best long-term outcomes for our clients.”

— John Doe, Chief Investment Officer

What’s next

Investors will be closely watching Bristol Myers Squibb's upcoming earnings report and any further changes in institutional ownership of the stock.

The takeaway

This filing highlights the dynamic nature of institutional investment decisions and the need for pharmaceutical companies to continuously demonstrate value to maintain the confidence of major shareholders.